Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
2.240
-0.220 (-8.94%)
At close: Apr 28, 2026, 4:00 PM EDT
2.410
+0.170 (7.59%)
Pre-market: Apr 29, 2026, 8:35 AM EDT
Lantern Pharma Employees
Lantern Pharma had 16 employees as of December 31, 2025. The number of employees decreased by 8 or -33.33% compared to the previous year.
Employees
16
Change (1Y)
-8
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$1,069,965
Market Cap
25.11M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Longeveron | 38 |
| Kyntra Bio | 34 |
| Lisata Therapeutics | 21 |
| ABVC BioPharma | 19 |
| NeuroSense Therapeutics | 17 |
| BriaCell Therapeutics | 16 |
| Apollomics | 13 |
| Neuphoria Therapeutics | 8 |
LTRN News
- 17 minutes ago - Lantern Pharma's predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally - Business Wire
- 5 days ago - Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut - Business Wire
- 9 days ago - Emerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity - Business Wire
- 12 days ago - Lantern Pharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators - Transcripts
- 15 days ago - Lantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22 - Business Wire
- 27 days ago - Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026 - Business Wire
- 4 weeks ago - Lantern Pharma Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Business Wire